Prescription medicine
Fluconazole Brand names: Diflucan
Fluconazole (Diflucan) is a prescription medicine with an FDA approval on record since 1990. FDA's NDC Directory lists it from 41 generic labelers, and pharmacies paid $0.380 per fluconazole 200 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the fluconazole FDA label on DailyMed (effective April 7, 2026, Zydus Pharmaceuticals (USA) Inc.); the NDA 19950 record on Drugs@FDA; every fluconazole label on DailyMed.
Highlights of the record
FDA label of April 7, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ).
Forms and strengths
- 50 mg
- 100 mg
- 150 mg
- 200 mg
- 2 mg/ml
- 10 mg/ml
- 40 mg/ml
- 200 mg/100ml
- 400 mg/200ml
- 1400 mg/35ml
Tablet; powder for suspension; injection (solution); injection.
On the market
- Earliest approval on file
- January 29, 1990 Diflucan In Dextrose 5% In Plastic Container, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 38 first July 29, 2004; 19 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 43 of which 41 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.380 per tablet Fluconazole 200 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 18 since 2013 0 Class I among all firms' recalls; latest July 11, 2018; 4 more by firms not listed as its makers
- FAERS reports
- 69,671 through July 30, 2026
What is fluconazole used for?
From the label: indications and usageFluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. […]
Conditions named in the indications of fluconazole's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Azole Antifungal.
Source: FDA drug label (fluconazole), Zydus Pharmaceuticals (USA) Inc., effective April 7, 2026 (SPL set d1364455-1537-46d4-b093-38cca3be778f), via openFDA; the full label on DailyMed
What does the patient leaflet for fluconazole say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking fluconazole tablets ?Fluconazole tablets can cause dizziness and seizures. Do not drive or operate machinery until you know how fluconazole tablets affects you.
From the patient leaflet: How should I store fluconazole tablets ?Store fluconazole tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep fluconazole tablets and all medicines out of the reach of children.
Source: FDA drug label (Fluconazole), Aurobindo Pharma Limited, effective November 14, 2024 (SPL set 6ebf24fd-41cd-4b3c-8176-a1436253ba2d), via openFDA; the full label on DailyMed
Is there a generic for fluconazole (Diflucan)?
The FDA approved the first generic fluconazole on July 29, 2004. 38 generic applications are approved; 19 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists fluconazole from 41 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1990 earliest approval on file
- 2004 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for fluconazole (Diflucan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.380 per Fluconazole 200 mg tablet, down 10% from $0.424 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Fluconazole 200 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Fluconazole 10 mg/mL suspension | Generic | $0.278 per mL | n/a | -4% |
| Fluconazole 100 mg tablet | Generic | $0.223 per tablet | $6.68 | -24% |
| Fluconazole 150 mg tablet | Generic | $0.470 per tablet | $14.09 | -20% |
| Fluconazole 200 mg tablet | Generic | $0.380 per tablet | $11.39 | -10% |
| Fluconazole 40 mg/mL suspension | Generic | $0.547 per mL | n/a | -4% |
| Fluconazole 50 mg tablet | Generic | $0.208 per tablet | $6.23 | -29% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has fluconazole been recalled?
The FDA's Enforcement Report lists 22 recalls naming fluconazole since 2013: 0 Class I (the most serious), 17 Class II, 5 Class III; 0 still ongoing. 4 of them are by firms that FDA's NDC Directory does not list as a maker of fluconazole and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 27, 2022 | Class II | Sentara Infusion Services not a listed maker | Lack of sterility assurance |
| July 11, 2018 | Class III | Renaissance Lakewood, LLC | Superpotent Drug and Failed Stability Specifications: lot out of specification for elevated sodium chloride and elevated water vapor. |
| July 11, 2018 | Class III | Renaissance Lakewood, LLC | Failed Stability Specifications: lot out of specification for elevated water vapor. |
| July 11, 2018 | Class III | Renaissance Lakewood, LLC | Superpotent Drug: lots out of specification for elevated sodium chloride and fluconazole assay. |
| February 21, 2018 | Class II | Renaissance Lakewood, LLC | Labeling: Label mix-up - A complaint was received of one bag of Fluconazole Injection, Iso-Osmotic Sodium Chloride Diluent, USP, 2mg/mL, 50 mL found within the … |
| November 11, 2017 | Class III | Renaissance Lakewood, LLC | Superpotent |
| May 15, 2017 | Class II | Baxter Healthcare Corporation | Lack of assurance of sterility: customer complaints received for the presence of leaks. |
| March 10, 2017 | Class II | Claris Lifesciences Inc | Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the fluconazole label say about other medicines?
The fluconazole label names 57 other medicines in its interaction, contraindication or warning sections. The labels of 46 other medicines name fluconazole. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Abrocitinib | drug interactions | Abrocitinib Drug interaction studies indicate that when coadministered with fluconazole (strong inhibitor of CYP2C19; moderate inhibitor of CYP2C9 and CYP3A4), the systemic exposure of abrocitinib and its active metabolites increased. (See CLINICAL PHARMACOLOGY . ) Avoid concomitant use of abrocitinib with fluconazole. |
| Amiodarone | drug interactions | Amiodarone Concomitant administration of fluconazole with amiodarone may increase QT prolongation. |
| Amitriptyline | drug interactions | Amitriptyline, nortriptyline Fluconazole increases the effect of amitriptyline and nortriptyline. |
| Amlodipine | drug interactions | Calcium channel blockers Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. |
| Amphotericin b | drug interactions | Amphotericin B Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with Candida albicans, no interaction in intracranial infection with Cryptococcus neoformans, and antagonism of … |
| Atorvastatin | drug interactions | HMG-CoA reductase inhibitors The risk of myopathy and rhabdomyolysis increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). |
| Azithromycin | drug interactions | There was no significant pharmacokinetic interaction between fluconazole and azithromycin. |
| Carbamazepine | drug interactions | Carbamazepine Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. |
| Celecoxib | drug interactions | Celecoxib During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg), the celecoxib C max and AUC increased by 68% and 134%, respectively. |
| Cyclophosphamide | drug interactions | Dose adjustment of warfarin may be necessary. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies. ) Cyclophosphamide Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. |
| Cyclosporine | drug interactions | Cyclosporine Fluconazole significantly increases cyclosporine levels in renal transplant patients with or without renal impairment. |
| Diclofenac | drug interactions | Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other non-steroidal anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). |
| Elexacaftor and ivacaftor and tezacaftor | drug interactions | Ivacaftor and fixed dose ivacaftor combinations (e.g., tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor) Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold. |
| Erythromycin | contraindications | Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. ( See CLINICAL PHARMACOLOGY: |
Every other medicine the fluconazole label names
| Medicine named | Section | What the label says |
|---|---|---|
| Felodipine | drug interactions | Calcium channel blockers Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. |
| Fentanyl | drug interactions | Furthermore, in a randomized crossover study with 12 healthy volunteers, it was shown that fluconazole delayed the elimination of fentanyl significantly. |
| Flurbiprofen | drug interactions | Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen … |
| Fluvastatin | drug interactions | … CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). |
| Glipizide | drug interactions | Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. |
| Glyburide | drug interactions | … reported from hypoglycemia in association with combined fluconazole and glyburide use. |
| Hydrochlorothiazide | drug interactions | Hydrochlorothiazide In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of … |
| Ibrutinib | drug interactions | Ibrutinib Moderate inhibitors of CYP3A4 such as fluconazole may increase plasma ibrutinib concentrations and increase risk of adverse reactions associated with ibrutinib. |
| Ibuprofen | drug interactions | Similarly, the C max and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) … |
| Isradipine | drug interactions | Calcium channel blockers Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. |
| Ivacaftor | drug interactions | Ivacaftor and fixed dose ivacaftor combinations (e.g., tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor) Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance … |
| Ivacaftor and tezacaftor | drug interactions | Ivacaftor and fixed dose ivacaftor combinations (e.g., tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor) Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance … |
| Lemborexant | drug interactions | Lemborexant Concomitant administration of fluconazole increased lemborexant C max and AUC by approximately 1.6-and 4.2-fold, respectively which is expected to increase risk of adverse reactions, such … |
| Levonorgestrel | drug interactions | There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. |
| Losartan | drug interactions | Losartan Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with … |
| Lurasidone | drug interactions | Lurasidone Concomitant use of moderate inhibitors of CYP3A4 such as fluconazole may increase lurasidone plasma concentrations. |
| Meloxicam | drug interactions | … (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). |
| Methadone | drug interactions | Methadone Fluconazole may enhance the serum concentration of methadone. |
| Midazolam | drug interactions | Short-acting benzodiazepines Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. |
| Naproxen | drug interactions | … anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). |
| Nifedipine | drug interactions | Calcium channel blockers Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. |
| Nortriptyline | drug interactions | Amitriptyline, nortriptyline Fluconazole increases the effect of amitriptyline and nortriptyline. |
| Olaparib | drug interactions | Olaparib Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. |
| Phenytoin | drug interactions | Drug Interaction Studies .) Phenytoin Fluconazole increases the plasma concentrations of phenytoin. |
| Pimozide | contraindications | Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients … |
| Prednisone | drug interactions | The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. |
| Quinidine | contraindications | Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients … |
| Rifabutin | drug interactions | Coadministration of fluconazole and quinidine is contraindicated. (See CONTRAINDICATIONS . ) Rifabutin There have been reports that an interaction exists when fluconazole is administered … |
| Rifampin | drug interactions | Drug Interaction Studies .) Rifampin Rifampin enhances the metabolism of concurrently administered fluconazole. |
| Simvastatin | drug interactions | … reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). |
| Sirolimus | drug interactions | Drug Interaction Studies .) Sirolimus Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. |
| Tacrolimus | drug interactions | Tacrolimus Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. |
| Theophylline | drug interactions | Drug Interaction Studies .) Theophylline Fluconazole increases the serum concentrations of theophylline. |
| Tofacitinib | drug interactions | Drug Interaction Studies .) Tofacitinib Systemic exposure to tofacitinib is increased when tofacitinib is coadministered with fluconazole. |
| Tolvaptan | drug interactions | Drug Interaction Studies. ) Tolvaptan Plasma exposure to tolvaptan is significantly increased (200% in AUC; |
| Triazolam | drug interactions | Triazolam Fluconazole increases the AUC of triazolam (single dose) by approximately 50%, C max by 20% to 32%, and increases t½ by 25% to 50 % due to the inhibition of metabolism of triazolam. |
| Verapamil | drug interactions | Calcium channel blockers Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. |
| Vinblastine | drug interactions | Vinca alkaloids Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an … |
| Vincristine | drug interactions | Vinca alkaloids Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an … |
| Vitamin a | drug interactions | Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related … |
| Voriconazole | drug interactions | Voriconazole Avoid concomitant administration of voriconazole and fluconazole. |
| Warfarin | drug interactions | … prothrombin time in patients receiving fluconazole concurrently with warfarin. |
| Zidovudine | drug interactions | Drug Interaction Studies. ) Zidovudine Fluconazole increases the C max and AUC of zidovudine by 84% and 74%, respectively, due to an approximately 45% decrease in oral zidovudine clearance. |
Other labels that name fluconazole
- Aficamten
- Bosentan
- Carvedilol
- Clarithromycin
- Clobazam
- Colchicine
- Darifenacin
- Dienogest and estradiol
- Dihydroergotamine
- Dronabinol
- Drospirenone and estradiol
- Drospirenone and ethinyl estradiol
- Drospirenone and ethinyl estradiol and levomefolate
- Eplerenone
- Estradiol
- Ethinyl estradiol and ferrous bisglycinate and levonorgestrel
- Ethinyl estradiol and ferrous fumarate and levonorgestrel
- Ethinyl estradiol and levonorgestrel
- Ethinyl estradiol and norelgestromin
- Ethinyl estradiol and norgestimate
- Ethinyl estradiol and segesterone
- Etonogestrel
- Etrasimod arginine
- Everolimus
- Fesoterodine
- Glimepiride
- Guanfacine
- Lorlatinib
- Macitentan
- Naldemedine
- Nateglinide
- Nevirapine
- Norethindrone
- Ospemifene
- Pacritinib
- Propranolol
- Rilpivirine
- Ruxolitinib
- Seladelpar lysine
- Selumetinib
- Torsemide
- Ubrogepant
- Voclosporin
- Zafirlukast
Source: FDA drug label (fluconazole), Zydus Pharmaceuticals (USA) Inc., effective April 7, 2026 (SPL set d1364455-1537-46d4-b093-38cca3be778f), via openFDA; the full label on DailyMed
What do FAERS reports show for fluconazole?
The FDA Adverse Event Reporting System holds 69,671 reports that list fluconazole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 12,476 are coded as a death and 30,560 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as fluconazole?
8 other medicines are given the same way (oral) and in the same FDA class as fluconazole or labeled mainly for the same use (fungal infections), the same class first. Fungal infections lists all 33 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Voriconazole | Fungal infections | 21 labelers | $1.88 per tablet 200 mg tablet | A presentation being discontinued |
| Posaconazole | Fungal infections | 21 labelers | $2.03 per tablet 100 mg tablet | A presentation being discontinued |
| Itraconazole | Fungal infections | 11 labelers | $0.910 per capsule 100 mg capsule | A presentation being discontinued |
| Clotrimazole | Fungal infections | 3 labelers | $0.292 per troche 10 mg troche | No current entry |
| Terbinafine | Fungal infections | 22 labelers | $0.143 per tablet 250 mg tablet | No current entry |
| Nystatin | Fungal infections | 21 labelers | $0.0569 per mL 100,000 unit/mL suspension | No current entry |
| Griseofulvin | Fungal infections | 10 labelers | $3.74 per tablet 250 mg tablet | No current entry |
| Flucytosine | Fungal infections | 9 labelers | n/a | No current entry |
Every medicine labeled for the same conditions as fluconazole
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does fluconazole compare with medicines for the same use?
12 side-by-side pages set fluconazole beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to fluconazole
- 8 medicines for the same use
- Other azole antifungals
- the pharmacologic class, with prices and generics
- Fluconazole side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other